Background: Previous recurrence risk models offered individualized prediction using a more diverse set of factors than traditional staging measures American Joint Committee on Cancer Tumor Node Metastasis (AJCC TNM) Staging System. Several studies have demonstrated gene mutation as a new prognostic factor, such as EGFR, KRAS and so on. This study aimed to analyze a comprehensive and reliable Nomogram prognostic model to predict recurrence in stage IA lung adenocarcinoma (ADC) with radical resection. Method: This was a retrospective, single-center and case-control study. Clinicopathologic, genetic, therapeutic features and survival status were collected. Univariate and multivariate Cox proportional hazards model was conducted. The nomogram for recurrence prediction was developed using Cox proportional hazards regression. Three nomograms were established based on a) AJCC 8 th TNM Staging, b) multivariate analysis results and c) risk factors recorded in published references. The higher concordance index (C-index) of model identified better performance of nomogram. Result: 1499 patients with pathological stage IA ADC from Cancer Hospital, Chinese Academy of Medical Sciences from October 2012 to December 2015 were enrolled in this study. The recurrence rate was 3.5% (53/1499). No recurrence of 180 patients randomly selected and analyzed in this study. Median DFS was not reached. The C-index of AJCC 8th TNM staging and the nomogram based on multivariate analysis was 0.598 (95% CI 0.538-0.659) and 0.696 (95% CI 0.629-0.764), respectively. The nomogram established on prognostic factors in previous studies, which included gene mutation such as EGFR, KRAS and ALK, showed higher discrimination with C-index 0.833 (95% CI 0.786-0.880). Conclusion: This was the first individualized nomogram combining clinicopathologic features with genetic information to predict recurrence in ADC. The nomogram added with gene mutation status demonstrated superior predictive capability comparing to other nomograms based on traditional AJCC T staging and multivariate analysis. Our nomogram was more reliable to guide prognostic factors and recurrence rate in stage IA ADC patients.
Background: Previous recurrence risk models offered individualized prediction using a more diverse set of factors than traditional staging measures American Joint Committee on Cancer Tumor Node Metastasis (AJCC TNM) Staging System. Several studies have demonstrated gene mutation as a new prognostic factor, such as EGFR, KRAS and so on. This study aimed to analyze a comprehensive and reliable Nomogram prognostic model to predict recurrence in stage IA lung adenocarcinoma (ADC) with radical resection. Method: This was a retrospective, single-center and case-control study. Clinicopathologic, genetic, therapeutic features and survival status were collected. Univariate and multivariate Cox proportional hazards model was conducted. The nomogram for recurrence prediction was developed using Cox proportional hazards regression. Three nomograms were established based on a) AJCC 8 th TNM Staging, b) multivariate analysis results and c) risk factors recorded in published references. The higher concordance index (C-index) of model identified better performance of nomogram. Result: 1499 patients with pathological stage IA ADC from Cancer Hospital, Chinese Academy of Medical Sciences from October 2012 to December 2015 were enrolled in this study. The recurrence rate was 3.5% (53/1499). No recurrence of 180 patients randomly selected and analyzed in this study. Median DFS was not reached. The C-index of AJCC 8th TNM staging and the nomogram based on multivariate analysis was 0.598 (95% CI 0.538-0.659) and 0.696 (95% CI 0.629-0.764), respectively. The nomogram established on prognostic factors in previous studies, which included gene mutation such as EGFR, KRAS and ALK, showed higher discrimination with C-index 0.833 (95% CI 0.786-0.880). Conclusion: This was the first individualized nomogram combining clinicopathologic features with genetic information to predict recurrence in ADC. The nomogram added with gene mutation status demonstrated superior predictive capability comparing to other nomograms based on traditional AJCC T staging and multivariate analysis. Our nomogram was more reliable to guide prognostic factors and recurrence rate in stage IA ADC patients. risks, cosmesis, travel burden, and functional outcomes throughout the course of treatment. Method: From 2012-2017, of the 206 consented patients, 184 lung and esophageal surgical patients were prospectively enrolled in this observational cohort study. Participants were asked to complete a RAND36 short form health survey (SF-36), which measures functional outcomes. They also completed the PROMIS questionnaire, which measures expectations regarding travel burden, pain, complications, and cosmesis on a continuous visual analog scale (VAS). The PROMIS questions were also classified into three anatomic regions (neck, chest, and abdomen). Patients were surveyed pre-operatively, at 1 month and at 6 months. McNemar's test, and paired and independent t-test were used as appropriate. Result: Of 206 patients, 184 (89%) completed the survey at least once. SF-36 showed physical functioning, role limitations due to physical health, energy level, pain, and social functioning worsened significantly at 1 month. All indices recovered to baseline at 6 months. Recovery of indices was similar in both MIS and open surgery patients. Patients indicated that pain after surgery (mean VAS ¼ 7.3; 95% CI 6.9-7.6) was more important than size of incision (mean VAS ¼ 4.5; 95% CI 3.9-5.1, p < 0.001) and travel burden (mean VAS ¼ 4.0; 95% CI 3.4-4.5, p < 0.001). The risk of complications (mean VAS ¼ 7.5; 95% CI 7.2-7.9) was more important than size of incision (mean VAS ¼ 4.5; 95% CI 3.9-5.1, p < 0.001) and travel burden (mean VAS ¼ 4.0; 95% CI 3.4-4.5, p < 0.001). These findings were similar at each time point and across each body regions. The MIS group perceived pain following surgery (mean VAS ¼ 7.12; 95% CI 6.35-7.89) was more important than the open group though it was not statistically different (mean VAS ¼ 6.02; 95% CI 5.25-6.79, p ¼ 0.07). Conclusion: Early postoperative deterioration followed by 6-month recovery in functional outcomes was reported by all patients regardless of surgical approach (MIS vs. open Background: In last decades several changes have been observed in lung cancer incidence, morphology, diagnostic and treatment options. However, only a few studies have focused on these changes among surgically treated patients. The aim of the current study was to analyse changes in lung cancer surgical treatment, comparing surgically treated patients with all lung cancer patients. Method: Data on all surgically treated lung cancer patients in Estonia from January 2000 to December 2015 were obtained from hospitals' medical records. Data on all patients diagnosed with lung cancer in the same period were obtained from the Estonian Cancer Registry. For analysis the study period was divided into 4-year time periods. Result: During the study period 2075 patients (1582 male, 493 female) with mean age 65 (range 10À89) years had been treated surgically in Estonia. The number of patients diagnosed with lung cancer did not change in the 16 years, but proportion of patients treated surgically increased from 13% to 19%. Among surgically treated patients the proportion of women increased from 18% to 31%; while this change among all lung cancer patients was from 20% to 27%. The proportion of younger patients (<60 years) among
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